DXCM Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 13.62% compared to DexCom's net margin of 12.41%. DexCom's return on equity of 26.6% beat Boston Scientific's return on equity of 8.96%.

DexCom has a consensus price target of $100.09, signalling upside risk potential of 49.74%. On the other hand Boston Scientific has an analysts' consensus of $115.37 which suggests that it could grow by 19.22%. Given that DexCom has higher upside potential than Boston Scientific, analysts believe DexCom is more attractive than Boston Scientific.

DexCom has a beta of 1.500, which suggesting that the stock is 49.959% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are smaller than Boston Scientific quarterly revenues of $4.6B. DexCom's net income of $151.7M is lower than Boston Scientific's net income of $566M. Notably, DexCom's price-to-earnings ratio is 46.74x while Boston Scientific's PE ratio is 77.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 6.84x versus 8.59x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies has a net margin of 13.62% compared to DexCom's net margin of -0.81%. DexCom's return on equity of 26.6% beat iRhythm Technologies's return on equity of -100.75%.

DexCom has a consensus price target of $100.09, signalling upside risk potential of 49.74%. On the other hand iRhythm Technologies has an analysts' consensus of $133.00 which suggests that it could grow by 28.57%. Given that DexCom has higher upside potential than iRhythm Technologies, analysts believe DexCom is more attractive than iRhythm Technologies.

DexCom has a beta of 1.500, which suggesting that the stock is 49.959% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.450, suggesting its more volatile than the S&P 500 by 44.979%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are larger than iRhythm Technologies quarterly revenues of $164.3M. DexCom's net income of $151.7M is higher than iRhythm Technologies's net income of -$1.3M. Notably, DexCom's price-to-earnings ratio is 46.74x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 6.84x versus 5.45x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 13.62% compared to DexCom's net margin of -58.2%. DexCom's return on equity of 26.6% beat Masimo's return on equity of -23.05%.

DexCom has a consensus price target of $100.09, signalling upside risk potential of 49.74%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 18.91%. Given that DexCom has higher upside potential than Masimo, analysts believe DexCom is more attractive than Masimo.

DexCom has a beta of 1.500, which suggesting that the stock is 49.959% more volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are larger than Masimo quarterly revenues of $600.7M. DexCom's net income of $151.7M is higher than Masimo's net income of -$349.6M. Notably, DexCom's price-to-earnings ratio is 46.74x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 6.84x versus 4.25x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 13.62% compared to DexCom's net margin of 16.85%. DexCom's return on equity of 26.6% beat Insulet's return on equity of 43.11%.

DexCom has a consensus price target of $100.09, signalling upside risk potential of 49.74%. On the other hand Insulet has an analysts' consensus of $312.92 which suggests that it could grow by 18.21%. Given that DexCom has higher upside potential than Insulet, analysts believe DexCom is more attractive than Insulet.

DexCom has a beta of 1.500, which suggesting that the stock is 49.959% more volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are larger than Insulet quarterly revenues of $597.5M. DexCom's net income of $151.7M is higher than Insulet's net income of $100.7M. Notably, DexCom's price-to-earnings ratio is 46.74x while Insulet's PE ratio is 45.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 6.84x versus 9.44x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.